Shionogi to Begin PII/III Study for Oral COVID-19 Drug on Sept. 27: President

Shionogi plans to kick off a PII/III clinical study for its oral COVID-19 treatment S-217622 in Japan on September 27, aiming to collect data in early December to seek regulatory approval, according to President Isao Teshirogi. Dr Teshirogi revealed the...read more